Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 14 of 259 for:    macular degeneration | Open Studies

Association of Previously Verified Gene Polymorphisms With AMD in Turkish Population (AMD-SNP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Kocatepe University
Sponsor:
Collaborator:
The Scientific and Technological Research Council of Turkey
Information provided by (Responsible Party):
Umit Ubeyt INAN, Kocatepe University
ClinicalTrials.gov Identifier:
NCT02248324
First received: September 20, 2014
Last updated: August 29, 2016
Last verified: August 2016
  Purpose
The purpose of this study is to determine whether common genetic polymorphisms that have been verified to be related to age-related macular degeneration (AMD) in some populations are also associated with AMD in Turkish population

Condition
Age-related Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Multicenter Study on the Investigation of Previously Verified Leading Gene Polymorphisms Related to Age-related Macular Degeneration in Turkish Population

Resource links provided by NLM:


Further study details as provided by Kocatepe University:

Primary Outcome Measures:
  • rate of homozygous, heterozygous or wild type genotype and allels [ Time Frame: at the end of third years ] [ Designated as safety issue: No ]
    Gene polymorphisms of 8 region with identification of homozygous, heterozygote and wild type genotyping and alleles


Secondary Outcome Measures:
  • Odds ratios for each genotyping in healthy elderly controls and patients with age related macular degeneration [ Time Frame: at the end of third years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Odds ratios for various combinations of gene regions between healthy elderly control and patients with age related macular degeneration [ Time Frame: at the end of third years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Whole blood

Estimated Enrollment: 5000
Study Start Date: November 2012
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   60 Years to 100 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with intermediate and advanced age related macular degeneration
Criteria

Inclusion Criteria:

  • Older age more than 50 years for the study group and older age more than 60 years for the control group
  • Intermediate or advanced stage age-related macular degeneration
  • Active or inactive scar choroidal neovascularization
  • For control patients: Normal macular anatomy and no sign of any stage of age-related macular degeneration

Exclusion Criteria:

  • People with findings of advanced age-related macular degeneration due to other reasons (inflammatory, myopic choroidal neovascularization etc..)
  • For control patients: Any sign of age-related macular degeneration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02248324

Contacts
Contact: Umit U INAN, MD +902722140600 uuinan@gmail.com
Contact: Handan Yildizus, PhD +905055044162 handanyildizus@yahoo.com

Locations
Turkey
Umit Ubeyt INAN Recruiting
Afyonkarahisar, Afyon, Turkey, 03200
Contact: Umit U Inan, MD    +905323248889    uuinan@gmail.com   
Contact: Handan YILDIZ, PhD    +905055044162    handanyildizus@yahoo.com   
Principal Investigator: Umit U INAN, MD         
Principal Investigator: Handan YILDIZUS, PhD         
Principal Investigator: Nilufer KOCAK, MD         
Principal Investigator: Banu OZTURK, MD         
Principal Investigator: Hurkan KERIMOGLU, MD         
Principal Investigator: Mujgan OZDEMIR, PhD         
Principal Investigator: Berkant KADERLI, MD         
Principal Investigator: Ozgur YALCINBAYIR, MD         
Principal Investigator: Mustafa DOGAN, MD         
Principal Investigator: Remzi AVCI, MD         
Principal Investigator: Suleyman KAYNAK, MD         
Principal Investigator: Suleyman DUNDAR, PhD         
Sponsors and Collaborators
Kocatepe University
The Scientific and Technological Research Council of Turkey
Investigators
Study Chair: Umit U INAN, MD Kocatepe University Medical School Department of Ophthalmology
  More Information

Publications:

Responsible Party: Umit Ubeyt INAN, Professor Doctor, Kocatepe University
ClinicalTrials.gov Identifier: NCT02248324     History of Changes
Other Study ID Numbers: 0112S269 
Study First Received: September 20, 2014
Last Updated: August 29, 2016
Health Authority: Turkey: Ethics Committee
Turkey: Ministry of Health

Keywords provided by Kocatepe University:
Age-related macular degeneration, genetic polymorphisms

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on December 07, 2016